Fludarabine phosphate for the treatment of low grade lymphoid malignancy
dc.contributor.author | Whelan, JS | |
dc.contributor.author | Davis, CL | |
dc.contributor.author | Rule, Simon | |
dc.contributor.author | Ranson, M | |
dc.contributor.author | Smith, OP | |
dc.contributor.author | Mehta, AB | |
dc.contributor.author | Catovsky, D | |
dc.contributor.author | Rohatiner, AZS | |
dc.contributor.author | Lister, TA | |
dc.date.accessioned | 2018-10-30T04:30:08Z | |
dc.date.available | 2018-10-30T04:30:08Z | |
dc.date.issued | 1991-07 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.issn | 1532-1827 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/12679 | |
dc.description.abstract |
Thirty-four patients with previously treated, advanced, low grade NHL were treated with Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 intravenously, daily for 5 days (median number of cycles = 3, range 1-10). Complete remission (CR) was achieved in six and partial remission (PR) in a further seven. Overall, responses were seen in 11/23 patients (48%) with follicular lymphoma and in 2/11 (18%) with low grade, diffuse NHL. Fifteen patients with previously treated CLL and one patient with prolymphocytic leukaemia (PLL) were also treated as above (median no. of cycles = 3, range 1-6). A partial response was seen in three of the 11 evaluable patients with CLL and CR was achieved in the patient with PLL. There were four deaths due to infection and 19 further episodes requiring admission to hospital. No other significant toxicity was reported in a total of 164 cycles of Fludarabine. This agent is active in advanced low grade lymphoid malignancy. Further studies are required to assess its role in newly diagnosed patients. | |
dc.format.extent | 120-123 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.subject | Antineoplastic Agents | |
dc.subject | Drug Evaluation | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Leukemia, Lymphocytic, Chronic, B-Cell | |
dc.subject | Lymphoma, Non-Hodgkin | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Vidarabine | |
dc.subject | Vidarabine Phosphate | |
dc.title | Fludarabine phosphate for the treatment of low grade lymphoid malignancy | |
dc.type | journal-article | |
dc.type | Clinical Trial | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1991FW35100026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 1 | |
plymouth.volume | 64 | |
plymouth.publication-status | Published | |
plymouth.journal | British Journal of Cancer | |
dc.identifier.doi | 10.1038/bjc.1991.253 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dc.identifier.eissn | 1532-1827 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1038/bjc.1991.253 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Journal Article/Review |